A branded initiation dose is not a validated instruction for a compounded vial. FDA does not approve these pharmacy preparations or their dose ranges [3]. The prescriber must assess the actual product and clinical circumstances, and the pharmacist must reconcile the prescription with its label. For the product and regulatory background, start with our compounded tirzepatide guide.
What the adult Zepbound label says about initiation
Zepbound is the FDA-approved tirzepatide for weight and sleep apnea. Its label is direct about where to begin:
The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.[1]
Mounjaro, the tirzepatide brand for type 2 diabetes, starts at the same 2.5 mg once weekly [2]. Matching initiation numbers do not make every population, maintenance dose or formulation interchangeable; Mounjaro’s pediatric maximum differs from its adult maximum. The label also says why the start is low: the step-up schedule is there "to reduce the risk of gastrointestinal adverse reactions" such as nausea, vomiting and diarrhea [1].
Initiation and maintenance are different labeled purposes
The branded label describes gradual escalation to reduce gastrointestinal adverse reactions, with maintenance selection based on indication, response and tolerability [1]. That framework does not establish a stepwise schedule for an individual compounded prescription. Ask the clinician to explain the actual preparation and monitoring rather than use a website’s dose ladder.
| Reference | Labeled amount | Scope |
|---|---|---|
| Initiation | 2.5 mg weekly | Not approved for maintenance |
| Weight-management maintenance | 5, 10 or 15 mg weekly | Selected by the clinician using response and tolerability |
| Obstructive sleep-apnea maintenance | 10 or 15 mg weekly | Adults with obesity and the labeled sleep-apnea indication |
| Adult maximum | 15 mg weekly | Zepbound label; not proof that a compounded dose is appropriate |
The product label defines adult treatment instructions. This table does not provide a stepwise schedule or conversion for a compounded preparation [1].
The cited trial tested specific branded maintenance-dose arms; it does not establish every possible tirzepatide regimen. In SURMOUNT-1, adults with obesity or qualifying overweight, without diabetes, lost an average of 15.0% of body weight at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, against 3.1% on placebo [5]. No randomized maintenance arm stayed at 2.5 mg. That design supports a formulation- and regimen-specific interpretation, not a conclusion that every other dose has been exhaustively studied.
Compounded tirzepatide has no official dose because it has no approval
FDA states that compounded drugs "are not FDA approved," which means the agency doesn't review them for safety, effectiveness or quality before they're sold [3]. There's no compounded tirzepatide label written by FDA. The label on your vial comes from the pharmacy that made it.
The shortage-era enforcement discretion ended in 2025. Patient-specific compounding must still satisfy applicable conditions, including restrictions on essentially-copy products [4]. Your prescription sets the dose, and the pharmacy prepares a vial to match it. If you want the side-by-side on approval, evidence and price, read compounded tirzepatide vs Zepbound.
Your vial's numbers may not match anyone else's
This is the part that trips people up. Compounding pharmacies make tirzepatide at different strengths, so the amount of liquid for the same milligram dose differs from one pharmacy to the next, and sometimes between refills. A volume that's right for one person's vial can be wrong for yours.
That's why you won't find volumes or unit counts here, and why FDA "encourages patients to talk with their health care provider or compounder about how to measure and administer the intended dose" [3]. Ask your pharmacist to show you how your own label translates your prescribed milligrams. Then ask again whenever a refill arrives from a different pharmacy.
FDA reports distinguish measuring errors from above-label prescribing
FDA has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide. Patients measured incorrect doses, and in some cases health care professionals miscalculated them [3]. The agency also has reports tied to compounded semaglutide or tirzepatide prescribed beyond the approved label: bigger single doses, more frequent doses, or faster increases.
One published case report shows how far a measuring mistake can go. A 50-year-old woman reported accidentally injecting ten times her intended first dose of compounded semaglutide and developed severe swelling of the airway that needed four days on a ventilator [6]. The patient also had prior lisinopril-related angioedema and current valsartan exposure. This single semaglutide case describes a temporal association; it does not prove that the amount caused the reaction, quantify incidence or establish the same allergic mechanism for tirzepatide.
Questions to ask before your first dose
- What dose in milligrams is prescribed, why was it selected and what evidence supports this preparation?
- How do I measure that dose from this pharmacy's vial? Can the pharmacist show me?
- When will we talk about stepping up, and what would make us wait?
- What instructions apply to a missed dose of this exact preparation? Ask the prescriber rather than transfer a brand’s instructions yourself.
- Which side effects mean I should call you, and which mean urgent care?
- How long can I use this vial once it's opened?
That last question has an FDA answer for multi-dose vials of sterile medicine: use them within 28 days of first use, even if the compounder's instructions say longer [3]. The guide to compounded tirzepatide out of the fridge covers storage in full.
Switching from Zepbound or Mounjaro is a prescriber decision
If you're moving between brand and compounded tirzepatide, the brand labels offer no conversion for compounded products. Your prescriber reassesses the treatment rather than assuming a direct conversion, and the pharmacist confirms how that dose is measured from the new vial.
Some people ask about staying below the label doses on purpose. That's a different question, covered in the guide to microdosing tirzepatide. If you haven't chosen a source yet, how to get compounded tirzepatide legally explains what to check first, and is compounded tirzepatide safe? covers the safety record.